טוען...
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results(1)
Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB,...
שמור ב:
| הוצא לאור ב: | J Lipid Res |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The American Society for Biochemistry and Molecular Biology
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4808774/ https://ncbi.nlm.nih.gov/pubmed/26848137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M066399 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|